Komori
Medical Ikkou Group (3353) · RiskMaterialised

Impairment Risk for Fixed Assets and Goodwill

First written in FY2021. 5 of 12 entries say "Restated". Latest entry: FY2027-H1.

12entries
6years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY2023-Q3MaterialisedFY2023 – FY20252021: 220212022: 320222023: 220232024: 020242025: 120252026: 42026
Same theme, other companies

Medical Ikkou Group moved to the "Worse" side of this theme in 2023, 2 years after the typical company in this theme (2021).

The whole theme swung hardest in 2020: 51 of 96 companies on the "Worse" side.

67 other companies' latest entry also says "Materialised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 189 companies compared. The sentences above are computed from all 189.Comparing 200 of the theme's 420 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1MaterialisedAnnual report

    「Impairment loss - 10,947」

    The risk of impairment of property, plant and equipment and goodwill materialized during the interim consolidated accounting period, resulting in the recognition of an impairment loss of ¥10,947 thousand.
  2. 2026-10-09MaterialisedEarnings

    「減損損失 - 10,947」

    前年中間期は減損損失の計上がなかった一方、当中間期は10,947千円を計上しており、固定資産・のれんの減損リスクが実績に現れている。
  3. FY2026MitigatedAnnual report

    「During the current consolidated fiscal year, the company recorded an impairment loss of ¥36,239 thousand on 2 stores and other properties in Aichi and Osaka prefectures.」

    The impairment loss on fixed assets and goodwill was ¥1,648 thousand in the current fiscal year, a substantial decrease from ¥203,206 thousand in the previous fiscal year. No impairment loss on goodwill was recorded.
  4. 2026-04-28MitigatedGeneral Meetings of Shareholders

    「Impairment losses Dispensing pharmacy business — Healthcare business 1,648」

    Fixed-asset impairment losses for the consolidated fiscal year under review comprised only ¥1,648 thousand in the healthcare business, a substantial decrease from the ¥203,206 thousand reported for FY2025. The disclosure continues to refer to uncertainty in estimates of future cash flows and the possibility of recognising impairment losses.
  5. FY2025WorsenedAnnual report

    「During the current consolidated fiscal year, the company recorded an impairment loss of ¥36,239 thousand on 2 stores and other properties in Aichi and Osaka prefectures.」

    The impairment risk for fixed assets and goodwill materialised again during the current fiscal year, with the company recording total impairment losses of ¥203,206 thousand on stores, care facilities and other properties.
  6. FY2023MaterialisedAnnual report

    「During the current consolidated fiscal year, the company recorded an impairment loss of ¥36,239 thousand on 2 stores and other properties in Aichi and Osaka prefectures.」

    The impairment risk for fixed assets and goodwill materialised, and the company recorded impairment losses of ¥5,677 thousand on buildings and structures and ¥30,562 thousand on goodwill.
  7. FY2023-Q3RestatedAnnual report

    「The impact on the Group’s businesses differs by business, and although the Group was affected during the current consolidated fiscal year, it has made accounting estimates, including impairment accounting for fixed assets, on the assumption that conditions will gradually recover. There have been no material changes to the assumptions described in the annual securities report for the previous consolidated fiscal year. However, losses may arise if the spread of COVID-19 differs from expectations.」

    While there has been no material change in the accounting assumption that the impact of COVID-19 will gradually recover, the company continues to disclose the possibility of losses, including impairment losses on fixed assets, if the spread of infection differs from expectations.
  8. FY2023-Q2RestatedAnnual report

    「The impact on the Group’s businesses differs by business, and although the Group was affected during the current consolidated fiscal year, it has made accounting estimates, including impairment accounting for fixed assets, on the assumption that conditions will gradually recover. There have been no material changes to the assumptions described in the annual securities report for the previous consolidated fiscal year. However, losses may arise if the spread of COVID-19 differs from expectations.」

    While there has been no material change in the assumption that the impact of COVID-19 will gradually recover, the company continues to disclose the possibility of losses, including impairment losses on fixed assets, if the spread of infection differs from expectations.
  9. FY2023-Q1RestatedAnnual report

    「The impact on the Group’s businesses differs by business, and although the Group was affected during the current consolidated fiscal year, it has made accounting estimates, including impairment accounting for fixed assets, on the assumption that conditions will gradually recover. There have been no material changes to the assumptions described in the annual securities report for the previous consolidated fiscal year. However, losses may arise if the spread of COVID-19 differs from expectations.」

    While there has been no material change in the accounting assumption that the impact of COVID-19 will gradually recover, the company continues to disclose the possibility of losses, including impairment losses on fixed assets, if the spread of infection differs from expectations.
  10. FY2022-Q3RestatedAnnual report

    「The impact on the Group’s businesses differs by business, and although the Group was affected during the current consolidated fiscal year, it has made accounting estimates, including impairment accounting for fixed assets, on the assumption that conditions will gradually recover. There have been no material changes to the assumptions described in the annual securities report for the previous consolidated fiscal year. However, losses may arise if the spread of COVID-19 differs from expectations.」

    While there has been no material change in the accounting assumption that the impact of COVID-19 will gradually recover, the company continues to disclose the possibility of losses, including impairment losses on fixed assets, if the spread of infection differs from expectations.
  11. FY2022-Q1RestatedAnnual report

    「The impact on the Group’s businesses differs by business, and although the Group was affected during the current consolidated fiscal year, it has made accounting estimates, including impairment accounting for fixed assets, on the assumption that conditions will gradually recover. There have been no material changes to the assumptions described in the annual securities report for the previous consolidated fiscal year. However, losses may arise if the spread of COVID-19 differs from expectations.」

    While there has been no material change in the accounting assumption that the impact of COVID-19 will gradually recover, the company continues to disclose the possibility of losses, including impairment losses on fixed assets, if the spread of infection differs from expectations.
  12. FY2021First statedAnnual report

    「If the conditions or assumptions underlying the estimates change due to a revision of the business plan or changes in the business environment, an impairment loss on property, plant and equipment and other fixed assets may arise.」

    The disclosure states that impairment losses may arise on fixed assets at stores and care facilities and goodwill arising from business combinations due to changes in future cash flows or business plans.
Moved together

"Restructuring the Group through M&A and Subsidiary Mergers" moved the same way as this thread, in the same document, in 2 of its 12 moves.

222222★123456
  1. ★This thread
  2. 1Restructuring the Group through M&A and Subsidiary Mergers2×
  3. 2Profit Pressure from Intensifying Price Competition in the Pharmaceutical Wholesale Market2×
  4. 3Price fluctuation risk of investment securities2×
  5. 4Stable and Consistent Dividend Policy2×
  6. 5Impact of COVID-19 on Business Activities and Performance2×
  7. 6Infection Prevention Measures and Safety Assurance in Response to the Spread of COVID-192×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Medical Ikkou Group yet. It last moved in the Earnings of 2026-10-09: "Materialised".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.